## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re: Application of DEBINSKI et al.

Serial No.:

10/075,823

Examiner:

RECEIVED

JAN 0 8 2003

TECH CENTER 1800 12800

Date Filed:

February 12, 2002

Group:

For:

VEGF-D EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

Pursuant to the Duty to Disclose under 37 CFR 1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed.

The claimed invention is believed patentable over the disclosures enclosed. This citation is intended to give the Examiner an opportunity to make an independent evaluation. No representations are made regarding these materials.

Respectfully submitted,

**AKERMAN SENTERFITT** 

Dated: January 2, 2003

Registration No. 42,730

222 Lakeview Avenue, Suite 400

West Palm Beach, FL 33402-3188

Tel: 561-653-5000

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of DEBINSKI et al.

Serial No.:

10/075,823

Examiner:

Date Filed:

February 12, 2002

Group:

RECEIVED

JAN 0 8 2003

TECH CENTER 1600/2900

For:

VEGF-D EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for

# TRANSMITTAL LETTER

Commissioner for Patents Washington, DC 20231

Dear Sir:

Please find enclosed for filing the following:

Supplemental Information Disclosure Statement, with PTO-1449, and references; <u>X</u>

<u>X</u> 1 postcard.

Although no fee is believed due, please charge any underpayment to Deposit Account No. 50-0951. This letter is submitted in duplicate.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: January 2, 7003

Stariley AKim, Ph.D., Esq.

Registration No. 42,730

222 Lakeview Avenue, Suite 400 West Palm Beach, FL 33402-3188

Tel: 561-653-5000

Docket No. 6460-41

U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. 6460\_A1

ISCLOSURE STATEMENTO
APPLICANT

Sheet 1

Form PTO-144940EMAR (Rev. 2-88)

APPLICATION NO. 10/075,823

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Debinski et al.

FILING DATE February 12, 2002

GROUP

	· · · · · · · · · · · · · · · · · · ·	U.S.	PATENT DOCUMENTS			·
EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						<u> </u>
						·

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TR	ANSLATION
	NUMBER					YES	NO
							·

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- <del></del>	1 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
	Goldman et al., "Epidermal Growth Factor Stimulates Vascular Endothelial Growth Factor Production by Human Malignant Glioma Cells: A Model of Glioblastoma Multiforme Pathophysiology," Molecular Biology of the Cell, 4: 121-133, 1993
	Kerbel et al., "Establishing a Link between Oncogenes and Tumor Angiogenesis," Molecular Medicine, 4: 286-295, 1998
	Orlandini et al., "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascula endothelial growth factor family," Proc. Natl. Acad. Sci. USA, 93: 11675-11680, 1996
	Achen et al., "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," Proc. Natl. Acad. Sci. USA, 95: 548-553, 1998
	Marconcini et al., "c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro," Proc. Natl. Acad. Sci. USA, 96: 9671-9676, 1999
	Mintz A. and W. Debinski, "Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies," Critical Reviews in Oncogenesis, 11: 77-95, 200

**EXAMINER** 

DATE CONSIDERED

<sup>\*</sup> EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	JAN 0 6 2003				Sh	eet 2_ of 4_
AAPIS Form PTO-1449 (Rev. 2-88)	ATTY. DOCKET NO. 6460-41	10/075,				
INFO	DRMATION DISCL BY APPI	APPLICANT  Debinski et al.		JAN 0 8 200		
	Filing date February 12, 2002  TECH CENTER					
<del></del>		U.S	. PATENT DOCUMENTS			
EXAMINER'S INITIAL	DÖCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		FORE	IGN PATENT DOCUMEN	rs		
	DOCUMENT NUMBER				SUBCLASS	TRANSLATION  YES NO
					i	
	OTHE	R DOCUMENTS (1	Including Author, Title, Date	Pertinent Pages, Etc.)		
	OTHE					
	Achen et al.,	"Monoclonal antib or-2 and VEGF re	podies to vascular endothe eceptor-3," Eur. J. Biochen	lial growth factor-D n. 267: 2505-2515, 2	olock its interac	tions with both
	Achen et al., VEGF recept	or-2 and VEGF re	oodies to vascular endothe ceptor-3," Eur. J. Biochen Vascular Endothelial Gro dimers," The Journal of B	n. 267: 2505-2515, 20 ovth Factor-D Involve	000 s Proteolytic Pr	ocessing Which
	Achen et al., VEGF recept Stacker et al., Generates No	or-2 and VEGF re "Biosynthesis of on-covalent Homog	vascular Endothelial Grodiners," The Journal of Boon of newly established hu	n. 267: 2505-2515, 20 wth Factor-D Involve ological Chemistry, 2	000 s Proteolytic Pr 274: 32127-321	rocessing Which 36, 1999
	Achen et al., VEGF recept Stacker et al., Generates No Halfter et al., Journal of No	"Biosynthesis of in-covalent Homo "Growth inhibitio turo Oncology, 39	vascular Endothelial Grodiners," The Journal of Boon of newly established hu	n. 267: 2505-2515, 20 wth Factor-D Involve ological Chemistry, 2 man glioma cell lines ne by AP-1 Is Media	s Proteolytic Pr 274: 32127-321 by leukemia in	rocessing Which 36, 1999  hibitory factor,"
	Achen et al., VEGF recept  Stacker et al., Generates No  Halfter et al., Journal of No  Bergers et al. First Intron,"	"Biosynthesis of in-covalent Homod "Growth inhibition turo Oncology, 39 "Transcriptional Molecular and Ce	Vascular Endothelial Grodimers," The Journal of Bion of newly established hu: 1-18, 1998  Activation of the fra-1 Gellular Biology, 15: 3748-2 mbers: regulation, structure	n. 267: 2505-2515, 20 wth Factor-D Involve ological Chemistry, 2 man glioma cell lines ne by AP-1 Is Media 758, 1995	s Proteolytic Pr 274: 32127-321 by leukemia in ted by Regulato	rocessing Which 36, 1999  thibitory factor,"
	Achen et al., VEGF recept  Stacker et al., Generates No  Halfter et al., Journal of No  Bergers et al. First Intron,"  Tulchinsky, I Histopathol,	"Biosynthesis of on-covalent Homosuro Oncology, 39, "Transcriptional Molecular and Cet., "Fos family me 15: 921-928, 2000	Vascular Endothelial Grodimers," The Journal of Bion of newly established hu: 1-18, 1998  Activation of the fra-1 Gellular Biology, 15: 3748-2 mbers: regulation, structure	n. 267: 2505-2515, 20 wth Factor-D Involve ological Chemistry, 2 man glioma cell lines ne by AP-1 Is Media 758, 1995 e and role in oncoge	s Proteolytic Pr 274: 32127-321 by leukemia in ted by Regulato	rocessing Which 36, 1999  chibitory factor,"  ory Sequences in the  con," Histol

JAN 0 6 2003						Si	neet 4 of	f 4
(Rev. 2-88)	U.S.	DEPARTMEN	T OF COMMERCE PATENT AND TRADEMARK OFFICE	атту. роск 6460-41		APPLICATIO	N NO.	
(	DRMATION DISCL BY APPL		EMENT	APPLICANT  Debins	ki et al.	REC	Ela	ED 2003
	(Use several shee	ts if necessary)		FILING DATE Februa	ry 12, 2002	GROUP JA	NOB	A 1800 [280
:		U.S	. PATENT DOCUMENTS				<u>renti</u>	, , , , , , , , , , , , , , , , , , ,
EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBOLASS	FIL	LING DATE
		FORE	IGN PATENT DOCUMENT	rs			J	
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	YES	ANSLATION NO
	ОТНЕ	DOCUMENTS (1	Including Author, Title, Date,	, Pertinent l	Pages, Etc.)		***	
	Strawn et al.,	"Flk-1 as a Target	for Tumor Growth Inhibi	tion," Cand	er Research	, 56: 3540-35	45, 199	6
	Prewett et al., Inhibits Tumo 5218, 1999	"Antivascular En r Angiogenesis ar	dothelial Growth Factor R nd Growth of Several Mou	leceptor (Foundation in the learning in the le	etal Liver Ki man Tumors	nase 1 Mono ," Cancer Res	clonal A search, 5	intibody i9: 5209-
	Rubenstein et		Antibody Treatment of Gl , 2: 306-314, 2000	ioblastoma	Prolongs Su	urvival But R	esults in	Increased
	Okada et al., '	Impact of oncoge	enes in tumor angiogenesis	s: Mutant K	-ras up-regu	ulation of vas	cular en	dothelial

growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells," Proc. Natl. Acad. Sci. USA, 95: 3609-3614, 1998 Stacker et al., "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics," Nature Medicine, 7: 186-191, 2001

**EXAMINER** 

DATE CONSIDERED

<sup>\*</sup> EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AN 0 6 2003 P.	•			•	٤	Sheet 3_	of 4 . 🚗
(Rev. 2-88)	U.S.		T OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6460-41	APPLICATION (75)	是[]	JED .
INFO	ORMATION DISCL BY APPL		EMENT	APPLICANT Debinski et al.	J.	,NO 8	- 2003
	(Use several sheet	ts if necessary)		Filing date February 12, 20	002 GROUP	CENT	ER 1000
<del></del>	<del></del>	U.S.	PATENT DOCUMENTS		/Re-		<u> </u>
EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		LING DATE PPROPRIA
							,
	·						
		FOREIG	GN PATENT DOCUMENT	·s			<u>;                                 </u>
	DOCUMENT	DATE			CURCI ACC	770	:::::: TIO
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	ANSLATIO NO
	OTHER	DOCUMENTS (Inc	cluding Author, Title, Date, I	Dartinant Dance Etc.)		<u>L</u>	
	Zagzag et al., "		nical Localization of Basic	<del>"</del>	Factor in Astro	cytomas	s," Cancer
	Botelho et al., 'Tissue Inhibito	'Oncostatin M Stin r of Metalloproteir	mulates c-Fos to Bind a Tr	ranscriptionally Resurnal of Biological C	ponsive AP-1 F Chemistry, 273:	Element 5211-5	within the 218, 1998
	Mohan et al., "0 Including Expre 10405-10412, 2	ession of Matrix M	ibit the Angiogenic Respo Metalloproteinase Gelatina	onse Stimulated by Fuse B," The Journal of	ibroblast Grow of Biological Cl	th Facto nemistry	or-2, v, 275:
	Nakano et al., " Neurosurg, 83:	Matrix metalloprof 298-307, 1995	teinases and tissue inhibit	tors of metalloprotei	nases in human	glioma	s," J.
	Millauer et al., 579, 1994	"Glioblastoma gro	with inhibited in vivo by a	dominant-negative	Flk-1 mutant,"	Nature,	367: 576-
	Takano et al., "G	Concentration of V " Cancer Research	Vascular Endothelial Grow h, 56: 2185-2190, 1996	vth Factor in the Ser	um and Tumor	Tissue o	of Brain